Somatic RAD51D loss-of-function in EOC: HRR panel inclusion (varies); PARPi consideration...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-RAD51D-SOMATIC-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | RAD51D somatic loss-of-function |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIB |
| Recommended combinations | niraparib (HRD-positive), olaparib + bevacizumab, rucaparib (LOH-high) |
| Evidence summary | Somatic RAD51D loss-of-function in EOC: HRR panel inclusion (varies); PARPi consideration in HRD-positive context. ESCAT IIB / OncoKB Level 3B. |
Notes
Reflex germline testing recommended.
Used By
No reverse references found in the YAML corpus.